These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 25671027

  • 1. Complications of new medications.
    Roldan CJ, Paniagua L.
    West J Emerg Med; 2015 Jan; 16(1):154-6. PubMed ID: 25671027
    [Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A, Blanco R.
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
    Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.
    Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
    [Abstract] [Full Text] [Related]

  • 5. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group.
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J, Ordoveza PA.
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate-related osteonecrosis of the jaws--a case report.
    Kamoh AK, Ogle O.
    Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
    Hoefert S, Schmitz I, Tannapfel A, Eufinger H.
    Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
    [Abstract] [Full Text] [Related]

  • 14. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F.
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [Abstract] [Full Text] [Related]

  • 15. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z, Agacayak F, Ilgun S, Tecimer C, Demir G, Eralp Y, Okkan S, Ozmen V.
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [Abstract] [Full Text] [Related]

  • 16. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.